Judith Warner speaks with Dr. Matthew Johnson about the state of psychedelic research today and the likelihood that certain drugs — MDMA and psilocybin specifically — could soon be approved for the treatment of conditions like addiction and PTSD. Psychedelics have long been known for their abilities to alter perception, but renewed interest by major research institutions in psychedelics’ ability to treat a range of common disorders has brought some of them to the precipice of FDA approval. DR. JOHNSON is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins University and a leader in the study of psychedelics for the treatment of addiction. A transcript of their conversation can be found at<a href="https://www.aventine.org/podcast"> Aventine.org/podcast</a>. To learn more about listener data and our privacy practices visit: <a href="https://www.audacyinc.com/privacy-policy">https://www.audacyinc.com/privacy-policy</a> Learn more about your ad choices. Visit <a href="https://podcastchoices.com/adchoices">https://podcastchoices.com/adchoices</a>

Judith Warner speaks with Dr. Matthew Johnson about the state of psychedelic research today and the likelihood that certain drugs — MDMA and psilocybin specifically — could soon be approved for the treatment of conditions like addiction and PTSD. Psychedelics have long been known for their abilities to alter perception, but renewed interest by major research institutions in psychedelics’ ability to treat a range of common disorders has brought some of them to the precipice of FDA approval. DR. JOHNSON is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins University and a leader in the study of psychedelics for the treatment of addiction. A transcript of their conversation can be found at Aventine.org/podcast. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Judith Warner speaks with Dr. Matthew Johnson about the state of psychedelic research today and the likelihood that certain drugs — MDMA and psilocybin specifically — could soon be approved for the treatment of conditions like addiction and PTSD. Psychedelics have long been known for their abilities to alter perception, but renewed interest by major research institutions in psychedelics’ ability to treat a range of common disorders has brought some of them to the precipice of FDA approval. DR. JOHNSON is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins University and a leader in the study of psychedelics for the treatment of addiction. A transcript of their conversation can be found at<a href="https://www.aventine.org/podcast" rel="noopener noreferrer"> Aventine.org/podcast</a>. To learn more about listener data and our privacy practices visit: <a href="https://www.audacyinc.com/privacy-policy" rel="noopener noreferrer">https://www.audacyinc.com/privacy-policy</a> Learn more about your ad choices. Visit <a href="https://podcastchoices.com/adchoices" rel="noopener noreferrer">https://podcastchoices.com/adchoices</a>

05: The Future of Psychedelics in Healthcare

Human beings are living longer than ever. Thanks to advances like vaccines, antibiotics, pasteurized milk and clean water, we’ve added more than 30 years to the average lifespan over the last 120 years. That’s more than was added in the previous 10,000 years combined. More recently, enormous progress has been made in our treatment of deadly conditions like heart disease and cancer, with mortality rates for each dropping by double digits. Now science is tackling a new challenge: Can we cure aging itself? In pursuit of this holy grail, longevity research has gone from a sleepy backwater to a multi billion dollar field, populated — yes — by plenty of hucksters, but also by Nobel laureates. The goal is to find out what causes us to age and what we can do to slow it down, or maybe even reverse it altogether. Could tweaking the right molecule buy us 20 more years, or are we maxed out? Can older brains be re-wired to function like younger brains? Do any so-called biohacks actually work? 
These are some of the questions we are tackling in this season of The World as You’ll Know It: The Future of Aging. With leading scientists in the fields of biology, neuroscience and medicine, we’ll look at the cutting-edge of aging research and what living longer could mean for all of us.

Technology

Human beings are living longer than ever. Thanks to advances like vaccines, antibiotics, pasteurized milk and clean water, we’ve added more than 30 years to the average lifespan over the last 120 years. That’s more than was added in the previous 10,000 years combined. More recently, enormous progress has been made in our treatment of deadly conditions like heart disease and cancer, with mortality rates for each dropping by double digits. Now science is tackling a new challenge: Can we cure aging itself? In pursuit of this holy grail, longevity research has gone from a sleepy backwater to a multi billion dollar field, populated — yes — by plenty of hucksters, but also by Nobel laureates. The goal is to find out what causes us to age and what we can do to slow it down, or maybe even reverse it altogether. Could tweaking the right molecule buy us 20 more years, or are we maxed out? Can older brains be re-wired to function like younger brains? Do any so-called biohacks actually work? These are some of the questions we are tackling in this season of The World as You’ll Know It: The Future of Aging. With leading scientists in the fields of biology, neuroscience and medicine, we’ll look at the cutting-edge of aging research and what living longer could mean for all of us.

Human beings are living longer than ever. Thanks to advances like vaccines, antibiotics, pasteurized milk and clean water, we’ve added more than 30 years to the average lifespan over the last 120 years. That’s more than was added in the previous 10,000 years combined. More recently, enormous progress has been made in our treatment of deadly conditions like heart disease and cancer, with mortality rates for each dropping by double digits. Now science is tackling a new challenge: Can we cure aging itself? In pursuit of this holy grail, longevity research has gone from a sleepy backwater to a multi billion dollar field, populated — yes — by plenty of hucksters, but also by Nobel laureates. The goal is to find out what causes us to age and what we can do to slow it down, or maybe even reverse it altogether. Could tweaking the right molecule buy us 20 more years, or are we maxed out? Can older brains be re-wired to function like younger brains? Do any so-called biohacks actually work?&nbsp;
These are some of the questions we are tackling in this season of The World as You’ll Know It: The Future of Aging. With leading scientists in the fields of biology, neuroscience and medicine, we’ll look at the cutting-edge of aging research and what living longer could mean for all of us.

Share 05: The Future of Psychedelics in Healthcare

Sign up to save your podcasts

05: The Future of Psychedelics in Healthcare

05: The Future of Psychedelics in Healthcare

More shows like The World as You’ll Know It: The Future Of Aging

Freakonomics Radio

The New Yorker Radio Hour

On the Media

Explain It to Me

The Gray Area with Sean Illing

Amicus With Dahlia Lithwick | Law, justice, and the courts

The Daily

Radio Atlantic

Stay Tuned with Preet

The Atlantic Interview

Why Is This Happening? The Chris Hayes Podcast

Interesting Times with Ross Douthat

Throughline

Hard Fork

The Ezra Klein Show